We believe a major medical intervention such as cancer or surgery should not automatically result in reduced quality of life. Our programs are designed with the needs of patients in mind. Our pathways are proven to result in significant overall improvements in health-related quality of life for patients.
Meet the Phase-B Team
Professor Tara Rampal, MBBS FRCA
FOUNDER AND MANAGING DIRECTOR OF PHASE-B
Professor Rampal is a Consultant Anaesthetist with a keen interest in Peri-Operative care and Population Health. She trained at the Barts and the London School of Anaesthesia where she was awarded the Excellence Award for Academic Achievement in 2008. Professor Rampal has a credible and commendable track record of developing world-class award-winning patient optimisation services. During her tenure at Medway NHS Foundation Trust (MFT) she led the development of the Prehab Unit. For her work, she received Enhance Recovery After Surgery Society (ERAS) award for the best perioperative success story (2019) as well as Chief Executive’s Scholarship for Brilliance. The latter facilitated her travel and observership of the prehab unit at McGill University in Montreal. While she led the Prehab Unit at MFT, the unit was rated outstanding by the Care Quality Commission (CQC) inspection of the Trust (2020) and featured on the BBC South East news (2020). She subsequently founded and leads the award-winning Kent and Medway Prehab™ programme, a pan-county multi-organisation collaborative helping cancer patients to get fitter through targeted physical and psychological support. It is supported by Public Health and Cancer Alliance. This programme was featured as a case study in the NHS-X digital playbook. As part of this initiative, she has published A collection of recipes. This booklet features delicious and nutritious recipes donated by outstanding British Chefs to aid the healing of people with cancer as they go through their survivalship journey. Rt. Hon Tracey Crouch is the patron of the Kent and Medway Prehab project. She is passionate about the potential of digital tools in changing the healthcare landscape and is a frequent speaker at events discussing innovation in healthcare. She has completed the Leadership in Population Health module at the King’s Fund London and is a visiting Senior Lecturer at the Canterbury Christ Church University.
ENGAGEMENT LEAD AND ADVISOR
Advisor and director with a focus on Medical Technology. Chairman of the Board at Bonäsudden Holding AB (Publ) and Board Member at Sydsvenska Hem AB (Publ). Leader with a successful track record in building and managing organisations in dynamic and fast-growing start-up environments as well as corporations. Karl holds a Master of Science degree from Chalmers University of Technology in Sweden.
Dr Nick Plowman, MA, MD, FRCR, FRCP
Internationally respected Oncologist, Dr. Plowman has been a Consultant Oncologist at St. Bartholomew’s Hospital and the Hospital for Sick Children in London for thirty-years. His research work has led to advances in medical practice worldwide including the introduction of aromatase inhibitors into breast cancer management and glucocorticoids into advanced prostate cancer management. Dr. Plowman works globally and has deep experience in the UK, EU, USA, and the Middle East. He was trained and qualified at Cambridge University. Dr. Plowman also consults, globally, to healthcare providers, pharmaceutical companies, medical device companies, diagnostic companies, Venture Capital. He also provides an expert opinion in medico-legal matters.
Mr Nathan Nagel is a lifescience/ clinical entrepreneur with 22 years’ experience with 12 years’ experience of being an executive director. He is currently the CEO of the Fratrem Group Ltd; Middle East Medical Portal and Oncology Commercial Services, Mentor to founders on the Capital Enterprise Cancer Tech Accelerator, Head of UK for CureMatch Genetics, Board Adviser to NHS and University companies. His past executive experience includes CEO at Gamlen Tableting Ltd (Pharmaceuticals), Managing Director of Sanyal Bio LLC (Liver disease), CEO of Neuro-Bio Ltd (Neuroscience), CEO of Oncology Pharma Ltd (Market research company), and Managing partner of LifeScience Ventures Ltd (Healthcare Venture Capital)